At some point I had a WAG that if shown to be effective and ultimately approved they would price it around $50k. That was based on the company's addressable patient population estimates for anti-PD-1 nonresponders in advanced melanoma (10,000) and the company's projected market potential numbers for the US ($500M). I have seen them throw out a $1B number as well in company slides; this may account for patients in Australia?
News 
Market Data 
Discover 
